GPN Vaccines’ Post

Heading to Washington, DC next week for World Vaccine Congress? Stop by booth #556 to learn how Microbiologics supports vaccine development with BSL-2 and BSL-3 custom virology and microbiology materials and assay services. #worldvaccinecongress #wvc2024

Southern Research is one of the few CROs in the US that can work with highly pathogenic agents. From SARS-CoV-2, RSV, MPox, and HPAI, we have the experience to support your infectious disease programs from discovery to clinic. This publication illustrates our unique capabilities to help advance your programs! Southern Research #infectiousdisease #researchcapabilities

🎙️💡 In this episode, hear from Cocrystal Pharma, Inc.’s Co-CEO and President, Dr. Sam Lee, about the company's innovative approach to antiviral drug development, including a closer look at the new strain of Avian flu and the future of pandemic preparedness. 🎧 Don’t miss Dr. Lee’s insights on targeting viral replication proteins and what sets Cocrystal Pharma’s structure-based drug discovery platform apart: https://buff.ly/4dYdcyp #RespiratoryViruses #AvianFlu #Coronavirus #AntiviralDrugs #Norovirus #RespiratoryVirus #Biotechnology #Influenza #LifeSciencePodcast #XtalksPodcast

Catalyst funding for pump-priming projects is available to support collaborations between BactiVac Network members in bacterial vaccinology to explore new approaches and strategies to advance their vaccines in partnership with LMICs and industry, and acquire the data to support substantive funding applications.  Hosted at the University of Birmingham the BactiVac Network fosters partnership, disseminates relevant information and provides catalyst project and training support with the aim of accelerating vaccine development for bacterial infections relevant to LMICs. The catalyst funds available for projects up to £50,000 for a maximum of 6 months duration. Projects are required to align to one of the following:  - Focus on pathogens with outbreak potential  - Tackle the global antimicrobial resistance (AMR) challenge Additionally, priority will be given to projects that: - Target the pre-clinical/clinical bottleneck  - Generate novel partnerships between UK, Industry, LMIC partners  - Demonstrate a clear plan for future funding potential  - Confirm that research governance is already in place Deadline to apply: 6 October 2024 Find out more and apply: https://lnkd.in/d6fTVpFA #funding #researchfunding #catalystfunding #bacterialvaccinology #immunotherapy #vaccinedevelopment #researchopportunities #antimicrobialresistance #pathogens #fundingopportunities #bactivac #universityofbirmingham 

Discover Our Impacts The OptiViVax consortium brings together academics, non-profits and industrial partners, with expertise in vaccine development, manufacturing, and clinical trials. The project will build on the expertise of its partners in P. vivaximmuno-biology, preclinical functional assays, vaccine development, controlled human malaria infection (CHMI) clinical models and improved GMP bio-manufacturing know-how, to further develop next-generation vaccines with improved efficacy. The objectives of OptiViVax will now integrate ambitious multi-disciplinary scientific and clinical approaches around the parasite’s lifecycle and will use our increased knowledge of P. vivax immuno-biology to further develop next-generation vaccines with improved efficacy. Led by Dr Anne Moore and Dr Sonja Vucen, University College Cork. ▶https://lnkd.in/e4CwY8u4 Science Foundation Ireland #SSPC15 #SSPCExpertise #health #biologics #vaccines #malaria #funding #collaboration

Selection of vaccine-candidate peptides from Mycobacterium avium subsp. paratuberculosis by in silico prediction, in vitro T-cell line proliferation, and in vivo immunogenicity https://lnkd.in/dB4dwjSv

[ 📊 CASE STUDY 📊 ] Small chemical molecules, fructans and other oligosaccharides are targets for which it is difficult to obtain antibodies due to their very small size and consequently low immunogenicity. Our teams have developed optimized strategies for conjugating small molecules to improve their immunogenicity. Combined with a tailored immunization and screening approach, BIOTEM’s development programs increase the chances of success and the production of high-quality antibodies. 𝑻𝒐 𝒇𝒊𝒏𝒅 𝒐𝒖𝒓 𝒎𝒐𝒓𝒆, 𝒅𝒐𝒘𝒏𝒍𝒐𝒂𝒅 𝒐𝒖𝒓 𝑪𝒂𝒔𝒆 𝑺𝒕𝒖𝒅𝒚! ➡ https://lnkd.in/dMpNEnRB 📧 Contact us: info@biotem.fr Université de Caen Normandie Université de Rouen Normandie #antibody #hybridoma #fructan #sugar #oligosaccharide #hapten #research #biotechnology

Our CEO, Dr. Christopher Locher, will present NEXT WEEK at OPTIONS XII for Control of Influenza in Brisbane, Australia, where he'll highlight our innovative flu vaccine candidate, VT-105! 💉✨ In his talk, "A Matrix 2 Protein Vaccine from Bacterial Vesicles Protects Against Diverse Strains of Influenza," Dr. Locher will share exciting preclinical results on VT-105’s ability to protect against H1N1 and H5N1. 🔬 Key Takeaways: 💡 VT-105 reduced viral loads and protected against disease in preclinical studies. 💡 Strong immune response with high antibody levels. 💡 Effective protection against H5N1 in preclinical studies. This breakthrough vaccine uses bacterial vesicles to deliver M2 protein, overcoming past challenges. As we move toward clinical development, VT-105 shows great potential to address the global flu threat. Stay tuned for more updates as we work to advance this cutting-edge vaccine candidate! #Influenza #H5N1 #Vaccines #Biotech #Innovation #PublicHealth #FluVaccine

Register now for the upcoming Charles River Webinar Reducing Viral Clearance Challenges Through Preventative Measures, featuring Tareq Jaber, Associate Director, Process Evaluation and Anja Tessarz, Associate Director R&D & SME Viral Clearance. Viral clearance (VC) studies are mandatory for biological treatments derived from human and/or animal sources like recombinant proteins, blood products, vaccines, and critical medical devices. These studies examine the potential removal and/or inactivation of adventitious and endogenous viruses during certain steps of the manufacturing purification process and ensure they’re safe for use in humans. However, despite existing regulatory guidelines, designing a VC study is often not as straightforward as you might expect. In this webinar you’ll be given an in-depth look at some of the challenges you may encounter and the steps you can take to ensure viral clearance study success. https://lnkd.in/eFsYRq5j

We found a cure for the common cold!!! Good, now that I have your attention Viritis Ltd developed a platform for creating specific anti-viral drugs against almost all viruses, our first indication is viruses that attack the respiratory system such as Influenza, COVID-19, and yes the common cold. Currently, at the preclinical stage, we are looking for early-stage investors and long-term partners who want to help us prevent the next viral outbreak #pharma #earlystageinvesotrs #biotech #antiviral #investment #COVID19 #Influenza #stratupnation #thecommoncold #earlystage #drugdevelopment